Live-attenuated Rift Valley fever virus vaccination leads to durable, protective immunity independent of sex in C57BL/6 mice

Clicks: 2
ID: 313425
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #390 of 432 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Rift Valley fever virus (RVFV) is a zoonotic arbovirus endemic to Africa and the Arabian Peninsula that can cause disease in humans and livestock. There are currently no licensed vaccines for human use, but several candidates are at the clinical trial stage including DDVaxTM, a preparation of live-attenuated RVFV lacking the nonstructural proteins NSs and NSm (ΔNSsΔNSm). Multiple pre-clinical studies have shown that ΔNSsΔNSm is safe and immunogenic. METHODS: The longitudinal study described in this manuscript examined the additional features of duration, sex and dose in immunogenicity and protection provided by ΔNSsΔNSm. Female and male 8-week-old C57BL/6 mice were vaccinated with either a low- or high-dose of ΔNSsΔNSm and humoral (via neutralization assay and ELISA) and cellular immunity (ELISPOT and flow cytometry) were assessed over a period of 6 months. A subset of animals were challenged with a lethal dose of wild type (WT) RVFV 6 months post-vaccination. RESULTS: All vaccinated animals were protected against lethal Rift Valley fever (RVF) disease 6 months post-vaccination independent of dose or sex. Humoral immunity in the form of RVFV-specific neutralizing and binding antibodies decreased over time but remained detectable at the end of the study. RVFV-specific CD4+ T cells also decreased by 6 months post-vaccination. In contrast, virus-specific polyfunctional CD8+ T cells persisted at comparable levels throughout the study. CONCLUSIONS: This work demonstrates that a single low-dose of ΔNSsΔNSm vaccine elicits a durable humoral and cellular immune response that persists over months and protects C57BL/6 mice against lethal RVF disease.
Reference Key
openalex_W7161293735 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Karina Mueller Brown, Angel M. Kindsvogel, Sarah E. Petnuch, Tracey Freeman, Nathan E Adam, Lindsay R Wilson, Lingqing Xu, Dominique J. Barbeau, Brian H. Bird, Anita K. McElroy
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag266
URL
https://doi.org/10.1093/infdis/jiag266
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.